The application period will run from Aug. 4 – Nov. 21, 2025 at 1 p.m. EST.
Applicants must be based at a Massachusetts not-for-profit research institution working as Principal Investigators on a project that is researching historically underfunded and understudied sectors of the life sciences.
Phase | Focus | Capital Funds | General Funds | Time |
---|---|---|---|---|
Phase I | Feasibility & early data | Up to $100,000 | Up to $100,000 | 1 Year |
Phase II | Translational validation | Up to $400,000 | Up to $200,000 | 2 Years |
Phase III | Partnership readiness | Up to $250,000 | Up to $100,000 | 1 Year |
Eligible applicants must meet the following criteria:
Applications will be evaluated through a competitive, peer-review process by a panel of external experts from academia and industry with domain expertise. Reviewers will score proposals based on the following:
Awardees and their institutions must remain in compliance with all applicable MLSC agreements and reporting requirements throughout the funding period.
Olaris is a precision diagnostics company that is on a mission to revolutionize how diseases are diagnosed and treated. By leveraging their CEREBRO platform (Comprehensive Early Responsive Evaluation of Biomarkers Related to Outcomes), which combines metabolomics and machine learning, they are able to harness the power of the body’s own communication system to discover and develop their pipeline of myOLARIS precision diagnostics.